• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cytek Biosciences Set to Join S&P SmallCap 600

    4/25/23 5:54:00 PM ET
    $ABT
    $CSII
    $CTKB
    $SPGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABT alert in real time by email

    NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    May 1, 2023

    S&P SmallCap 600

    Addition

    Cytek Biosciences

    CTKB

    Health Care



    S&P SmallCap 600

    Deletion

    Cardiovascular Systems

    CSII

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/cytek-biosciences-set-to-join-sp-smallcap-600-301807529.html

    SOURCE S&P Dow Jones Indices

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $CSII
    $CTKB
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    S&P Global Inc.
    $SPGI
    2/17/2026$575.00Buy
    BofA Securities
    Cytek Biosciences Inc.
    $CTKB
    12/2/2025$6.00Equal-Weight
    Morgan Stanley
    Abbott Laboratories
    $ABT
    10/10/2025$145.00Buy
    The Benchmark Company
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    Cytek Biosciences Inc.
    $CTKB
    5/9/2025$4.00Buy → Hold
    TD Cowen
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    More analyst ratings

    $ABT
    $CSII
    $CTKB
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Vita Coco Company Set to Join S&P SmallCap 600

    NEW YORK, March 20, 2026 /PRNewswire/ -- The Vita Coco Company Inc. (NASD: COCO) will replace TEGNA Inc. (NYSE:TGNA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 25. S&P MidCap 400 constituent Nexstar Media Group Inc. (NASD: NXST) has acquired TEGNA in a deal that closed today, March 20. Following is a summary of the change that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorMarch 25, 2026S&P SmallCap 600AdditionThe Vita Coco CompanyCOCOConsumer StaplesMarch 25, 2026S&P SmallCap 600DeletionTEGNATGNACommunication ServicesABOUT S&P DOW JONES INDICESS&P Dow Jones Indice

    3/20/26 6:06:00 PM ET
    $COCO
    $NXST
    $SPGI
    Beverages (Production/Distribution)
    Consumer Staples
    Broadcasting
    Industrials

    S&P Global: Era of Linear Energy Transition Has Ended as AI Demand and Geopolitics Reshape Markets

    New journal published ahead of 44th Annual CERAWeek explores the competing pressures driving energy markets and the impact of ongoing geopolitical uncertaintyAnalysis published amidst ongoing war in the Middle East, one of the most historically important moments in the global energy marketsNEW YORK, March 20, 2026 /PRNewswire/ -- S&P Global today released new research examining how the global energy landscape is being reshaped by geopolitics and competing priorities of affordability, reliability, competitiveness, and decarbonization.  The edition went to press amidst the evolving war in the Middle East with unprecedented volatility in energy markets.

    3/20/26 1:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Abbott acquisition of Exact Sciences set to close on March 23, 2026

    Announcement follows receipt of all regulatory clearances necessary for closingTransaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional peopleABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people. Together with Exact Sciences, Abbott will accelerate innovation, expand access

    3/20/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $575.00

    2/17/26 7:30:15 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Morgan Stanley resumed coverage on Cytek Biosciences with a new price target

    Morgan Stanley resumed coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $6.00

    12/2/25 8:24:49 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    SEC Filings

    View All

    SEC Form DEFA14A filed by Abbott Laboratories

    DEFA14A - ABBOTT LABORATORIES (0000001800) (Filer)

    3/13/26 4:01:21 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Abbott Laboratories

    DEF 14A - ABBOTT LABORATORIES (0000001800) (Filer)

    3/13/26 4:00:23 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    3/9/26 4:21:32 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Joly Hubert bought $997,459 worth of shares (2,500 units at $398.98), increasing direct ownership by 1,515% to 2,665 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/12/26 4:01:28 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF TECHNOLOGY OFFICER Yan Ming gifted 1,176,000 shares, decreasing direct ownership by 19% to 4,915,933 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    3/13/26 6:30:47 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Chin Richard converted options into 6,107 shares, increasing direct ownership by 60% to 16,285 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    3/12/26 4:41:17 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CHIEF LEGAL OFFICER Barnett Valerie converted options into 29,722 shares and covered exercise/tax liability with 11,748 shares, increasing direct ownership by 15% to 134,436 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    3/12/26 4:40:22 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    The Vita Coco Company Set to Join S&P SmallCap 600

    NEW YORK, March 20, 2026 /PRNewswire/ -- The Vita Coco Company Inc. (NASD: COCO) will replace TEGNA Inc. (NYSE:TGNA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 25. S&P MidCap 400 constituent Nexstar Media Group Inc. (NASD: NXST) has acquired TEGNA in a deal that closed today, March 20. Following is a summary of the change that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorMarch 25, 2026S&P SmallCap 600AdditionThe Vita Coco CompanyCOCOConsumer StaplesMarch 25, 2026S&P SmallCap 600DeletionTEGNATGNACommunication ServicesABOUT S&P DOW JONES INDICESS&P Dow Jones Indice

    3/20/26 6:06:00 PM ET
    $COCO
    $NXST
    $SPGI
    Beverages (Production/Distribution)
    Consumer Staples
    Broadcasting
    Industrials

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    S&P Global Appoints Chief Strategy Officer for Mobility Global Completing New Executive Leadership Team

    Martin Metzker to lead Strategy, Communications and Enterprise Marketing for Mobility Global in preparation for its planned separation into a standalone public companyNEW YORK, Feb. 19, 2026 /PRNewswire/ -- S&P Global (NYSE: SPGI) today announced the appointment of Martin Metzker as Chief Strategy Officer of S&P Global Mobility ("Mobility Global"), effective immediately. Mr. Metzker will be responsible for leading Mobility Global's Strategy function and overseeing Communications and Enterprise marketing for the business as it prepares for its planned separation from S&P Global into a standalone public company. Mr. Metzker joins the company from Boston Consulting Group, and will report to Bil

    2/19/26 4:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Financials

    Live finance-specific insights

    View All

    S&P Global Acquires Enertel AI Corporation to Enhance Power Market Offering

    Strengthens Power and Renewables Portfolio with Combined Long-Term and Short-Term Insights Delivers Best-in-Class AI-Powered Nodal Price Forecasts and Decision Tools for Physical Power Traders, Utilities and Asset Operators NEW YORK, March 18, 2026 /PRNewswire/ -- S&P Global today announced the completion of its acquisition of Enertel AI Corporation, a company specializing in AI and machine learning-driven short-term power price forecasting for North American electricity markets. These new capabilities will join S&P Global's Energy division which has established itself as the au

    3/18/26 8:30:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Enhances Capital IQ Pro with Expanded Fixed Income, Biopharma and Private Markets Data Content and AI Capabilities

    Drift AI acquisition and the integration of ProntoNLP boost platform's GenAI tooling for enhanced client impactAdds ProntoNLP sentiment analysis to AI-powered Document Intelligence and over 4 million structured securities to accelerate financial analysis Acquires Drift AI to integrate natural language financial modeling into Capital IQ Pro Excel Plugin NEW YORK, March 12, 2026 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced significant enhancements to its flagship S&P Capital IQ Pro platform that incorporate advanced artificial intelligence capabilities and expanded datasets to accelerate financial analysis and decision making. The updates include the addition of ProntoNLP analytics a

    3/12/26 8:30:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

    FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of

    2/26/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 4:35:51 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

    SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 1:42:15 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    2/22/24 7:07:27 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials